Clal Biotechnology Industries (XTAE:CBI) ROCE %: -62.45% (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

XTAE:CBI Clal Biotechnology Industries Ltd XTAE:CBI
18 GF Score
Price ₪0.24
! 3 Warning Signs
View Full Analysis

What is Clal Biotechnology Industries ROCE %?

Clal Biotechnology Industries XTAE:CBI 18 ROCE % is -62.45% as of Dec. 2025. GuruFocus rates XTAE:CBI with a GF Score™ of 18/100. The stock has 3 warning signs investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Clal Biotechnology Industries's annualized ROCE % for the quarter that ended in Dec. 2025 was -62.45%.

Clal Biotechnology Industries  (XTAE:CBI) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Clal Biotechnology Industries ROCE % Related Terms

Clal Biotechnology Industries ROCE % Historical Data

* Premium members only.

The historical data trend for Clal Biotechnology Industries's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Clal Biotechnology Industries ROCE % Chart

Clal Biotechnology Industries Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only 28.68 -12.66 -14.81 -71.72 -55.71

Clal Biotechnology Industries Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -36.29 -58.23 -91.76 -53.52 -62.45
XTAE:CBI
18GF Score
Clal Biotechnology Industries Ltd XTAE:CBI
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Clal Biotechnology Industries ROCE % Calculation

Clal Biotechnology Industries's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-20.047/( ( (67.688 - 19.996) + (41.828 - 17.556) )/ 2 )
=-20.047/( (47.692+24.272)/ 2 )
=-20.047/35.982
=-55.71 %

Clal Biotechnology Industries's ROCE % of for the quarter that ended in Dec. 2025 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Dec. 2025 )  (Q: Jun. 2025 )(Q: Dec. 2025 )
=-18.216/( ( (52.121 - 18.051) + (41.828 - 17.556) )/ 2 )
=-18.216/( ( 34.07 + 24.272 )/ 2 )
=-18.216/29.171
=-62.45 %

(1) Note: The EBIT data used here is two times the semi-annual (Dec. 2025) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -62.45% mean?
Clal Biotechnology Industries (XTAE:CBI) has a ROCE % of -62.45% as of Dec. 2025.
Is Clal Biotechnology Industries' ROCE % too high?
Clal Biotechnology Industries' current ROCE % is -62.45%. Overall, Clal Biotechnology Industries has a GF Score™ of 18/100, reflecting its overall financial health beyond just this single metric.
How does Clal Biotechnology Industries' ROCE % compare to VRTX and REGN?
Clal Biotechnology Industries' ROCE % of -62.45% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Clal Biotechnology Industries's current ROCE % is -62.45%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clal Biotechnology Industries stock overvalued right now?
Clal Biotechnology Industries (XTAE:CBI) has a current ROCE % of -62.45%. The current ROCE % is -62.45%. Clal Biotechnology Industries' overall GF Score™ is 18/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Clal Biotechnology Industries (XTAE:CBI), the current ROCE % is -62.45% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Clal Biotechnology Industries Business Description

Address Azrieli Center, Triangle Building, 45th Floor, Tel Aviv, ISR, 67023
Clal Biotechnology Industries Ltd is a life sciences investment company. The company invests in companies ranging from seed to maturity, both public and private. Its portfolio of investments includes from heavy industry to biotechnology, hi-tech and energy companies.
18GF Score

Get the complete analysis for XTAE:CBI

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₪0.24
Price